Inhibrx Biosciences, Inc. (INBX)

13,73 +0,30 (+2,23%) Börsenschluss: 04:00PM EDT

Inhibrx Biosciences, Inc.

11025 North Torrey Pines Road
Suite 140
La Jolla, CA 92037
United States
858-795-4220
https://inhibrx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Mark Paul Lappe	CEO, President & Chairman	N/A	N/A	1967
Ms. Kelly Devine Deck B.S., CPA, M.S.	Executive VP, CFO & Treasurer	N/A	N/A	1980
Dr. Ashraf Amanullah Ph.D.	Executive VP, Chief Technical Operations Officer	N/A	N/A	1968
Dr. Brendan P. Eckelman Ph.D.	Executive VP & Chief Scientific Officer	N/A	N/A	1979
Ms. Leah Pollema J.D.	VP & General Counsel	N/A	N/A	N/A
Dr. Charbel Helaihel Pharm.D.	Vice President of Marketing & Commercial Planning	N/A	N/A	N/A
Mr. Jeffrey J. Jensen	Executive VP & Chief Clinical Operations Officer	N/A	N/A	N/A
Dr. Josep Garcia Ph.D.	Executive VP & Chief Clinical Development Officer	N/A	N/A	N/A
Mr. David Matly M.B.A.	Executive VP and Chief Commercial & Business Development Officer	N/A	N/A	N/A
Dr. Carlos Bais Ph.D.	Executive Vice President of Translational Sciences	N/A	N/A	N/A

Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

Corporate Governance

Inhibrx Biosciences, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.